Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers
2010 (English)In: Breast Cancer Research, ISSN 1465-542X, Vol. 12, no 6, R102- p.Article in journal (Refereed) Published
This study provides evidence that the SMAD3 gene, which encodes a key regulatory protein in the transforming growth factor beta signalling pathway and is known to interact directly with BRCA2, may contribute to increased risk of breast cancer in BRCA2 mutation carriers. This finding suggests that genes with expression associated with BRCA1 and BRCA2 mutation status are enriched for the presence of common genetic modifiers of breast cancer risk in these populations.
Place, publisher, year, edition, pages
2010. Vol. 12, no 6, R102- p.
Cancer and Oncology
IdentifiersURN: urn:nbn:se:umu:diva-42731DOI: 10.1186/bcr2785ISI: 000288751500013PubMedID: 21114847OAI: oai:DiVA.org:umu-42731DiVA: diva2:410147